Evidence map›Paper›PMID 36141241›Full record

ArticleHealthcare (Basel, Switzerland)2022

European Health Data Space-An Opportunity Now to Grasp the Future of Data-Driven Healthcare.

Denis Horgan, Marian Hajduch, Marilena Vrana, Jeannette Soderberg, Nigel Hughes, Muhammad Imran Omar, Jonathan A Lal, Marta Kozaric, Fidelia Cascini, Verena Thaler and 4 more

Open access · goldAbstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Making the case for an International Childhood Cancer Data Partnership.Journal of the National Cancer Institute · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 7 countries.

Denis HorganEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Marian HajduchInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, 77900 Olomouc, Czech Republic.ORCID 0000-0002-4834-908X
Marilena VranaEuropean Heart Network, 1000 Brussels, Belgium.
Jeannette SoderbergJuvenile Diabetes Research Foundation, 68 Rue du Faubourg Saint Honoré, 75008 Paris, France.
Nigel HughesJanssen Pharmaceutica NV, 2340 Beerse, Belgium.
Muhammad Imran OmarAcademic Urology Unit, Health Sciences Building, University of Aberdeen, Aberdeen AB25 2ZD, UK.ORCID 0000-0002-1597-3126
Jonathan A LalDepartment of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Faculty of Engineering and Technology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India.
Marta KozaricEuropean Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Fidelia CasciniSection of Hygiene and Public Health, Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, 00168 Rome, Italy.ORCID 0000-0001-6499-0734
Verena ThalerMedTech Europe, 1000 Brussels, Belgium.
Oriol Solà-MoralesFHiTT-Fundació HiTT, 08015 Barcelona, Spain.
Mário RomãoIntel Corporation, 2550 Kontich, Belgium.
Frédéric DestrebecqEuropean Brain Council, 1000 Brussels, Belgium.
Edith Sky GrossEURORDIS-Rare Diseases Europe, 75014 Paris, France.
Sam Higginbottom Institute of Agriculture · INEuropean Heart Network · BEEuropean Organisation for Rare Diseases · FRInstitute of Molecular and Translational Medicine · CZJanssen (Belgium) · BEUniversità Cattolica del Sacro Cuore · ITUniversity of Aberdeen · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The May 2022 proposal from the European commission for a 'European health data space' envisages advantages for health from exploiting the growing mass of health data in Europe. However, key stakeholders have identified aspects that demand clarification to ensure success. Data will need to be freed from traditional silos to flow more easily and to cross artificial borders. Wide engagement will be necessary among healthcare professionals, researchers, and the patients and citizens that stand to gain the most but whose trust must be won if they are to allow use or transfer of their data. This paper aims to alert the wider scientific community to the impact the ongoing discussions among lawmakers will have. Based on the literature and the consensus findings of an expert multistakeholder panel organised by the European Alliance for Personalised Medicine (EAPM) in June 2022, it highlights the key issues at the intersection of science and policy, and the potential implications for health research for years, perhaps decades, to come.

Indexed as

access to datadatadata protectiondiagnosisEuropeanEU valuesgovernancehealthhealthcarehealth policypersonalised medicinepolicy frameworkpreventionspacetreatment

Identifiers

PMID36141241
PMCPMC9498352
OpenAlexW4293531827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.